Focusing our energy on saving lives

Similar documents
EKOS. Interventional Vascular 3 February, Imagine where we can go.

Varithena 3 rd February 2015

Committed to Delivering Affordable Proton Cancer Therapy. Energy Focused on Saving Lives

Jefferies Healthcare Conference

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Jefferies 2014 Global Healthcare Conference November Because people depend on us

GSK Oncology R&D Update

Michael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation

PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION

NHS Healthcare Science. Cumbria & NE LWAB. 4 th September 2018

JP MORGAN HEALTHCARE CONFERENCE DOW R. WILSON President and Chief Executive Officer 1 FOR INVESTOR USE ONLY

Investor Presentation

For personal use only

Proton Treatment. Keith Brown, Ph.D., CHP. Associate Director, Radiation Safety University of Pennsylvania

For personal use only

SHIELDING TECHNIQUES FOR CURRENT RADIATION THERAPY MODALITIES

USPSTF Draft Recommendations Investor Call. October 6, 2015

Plans for the Precision Cancer Medicine Institute University of Oxford

INVESTOR MEETING ASTRO 2013

Update on Exact Sciences Molecular CRC Screening Test. November 16 th, 2011

January 30, 2018 Dow Wilson President and Chief Executive Officer

MedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy

World leader in navigated, non-invasive brain stimulation therapy and diagnosis

Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference

PROGRESS IN HADRONTHERAPY

ACCELERATORS FOR HADRONTHERAPY

Use of Bubble Detectors to Characterize Neutron Dose Distribution in a Radiotherapy Treatment Room used for IMRT treatments

PATENCY-1 Top-Line Results

UK FEL R&D Plans Jim Clarke

Annual Shareholders Meeting

SCANNER & SERVICES OVERVIEW

Economic Implications of Advancements in Radiation Technology. Dramatic Growth of RT Capacity in the US

27 September Interim results for the six months ended 30 June 2018

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Cowen Investor Conference March confidently live life with ease

Important information

LivaNova Investor Day

SOUTHAMPTON UNIVERSITY HOSPITALS NHS TRUST CANCER CARE PHASE 2A+ BUSINESS CASE

Press release Regulated information

Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908)

High brightness electron beam for radiation therapy A new approach

Basic Press Information

DOSIMETRIC COMPARISION FOR RADIATION QUALITY IN HIGH ENERGY PHOTON BEAMS

Theralase Presents Dosimetry Planning at International World Congress

Revolutionizing how advanced heart disease is treated

Sarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington

Market Survey. Technical Description Irradiation Tests

Cavosonstat Phase 2 Trial Results. November 28 th, 2016

Ion Beam Therapy should we prioritise research on helium beams?

ONTARIO CANCER PLAN

Radiation protection in proton therapy

Pancreatic Cancer Treatment

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes

Beam Loss and Collimation in the ESS Linac

UK X-FEL National Laboratory Perspective

Brisa Concessão Rodoviária. 1Q 2017 Traffic Update

DS-8201 Strategic Collaboration

Neovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum

SUMITOMO Particle Therapy Technologies

XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease

Important Notices. BASIS CPD Points PN/50971/1516/g

OncoSec Provides 2018 Business Outlook

New Ideas. Better Medicines. Third Quarter Financial Results Conference Call

PLEO-CMT Top-line Results. Presentation October 16, 2018

FORM8-K HILLENBRAND,INC.

8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks

Diagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014

Amendment No. 2. Item No. 2 (Rfx/ Event number )

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer

Medical Use of Radioisotopes

TECHNOLOGY & INNOVATION

Maintenance and Logistics Experience at Loma Linda Proton Treatment Facility

Tamsulosin Hydrochloride 0.4 mg Capsule

Genomic Health. Kim Popovits, Chairman, CEO and President

pat hways Medtech innovation briefing Published: 24 August 2018 nice.org.uk/guidance/mib157

Elekta - a partner and world-leading supplier

Annual Stockholder Meeting May 30, confidently live life with ease

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018

Elekta Infinity. Digital accelerator for advanced treatments. Redefining treatment precision, speed and control

Theralase Therapeutic Laser Technology Enhances Cancer Destruction

Clinical oncology workforce: the case for expansion Faculty of Clinical Oncology

The Heidelberg Ion Therapy Center. Thomas Haberer Heidelberg Ion Therapy Center Hadron Therapy Workshop, Erice 2009

COURSE LISTING. Courses Listed. Training for Cloud with SAP Hybris in Service Cloud (C4C) 23 August 2018 (06:31 BST) Fortgeschrittene.

Changing Paradigms in Radiotherapy

Introducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST)

Characterization and implementation of Pencil Beam Scanning proton therapy techniques: from spot scanning to continuous scanning

Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Lecture 13 Radiation Onclolgy

PSMA-617 License Transaction. October 2, 2017

ASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call

Acorda Acquisition of Civitas Therapeutics. September 24, 2014

Not an Offer for Securities

A Rare Opportunity in Transplant.

Announcing FDA Approval of GOCOVRI TM

About Cancer Research UK

February 23, Q4 and Year-End 2016 Financial Results

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

Utrophin Modulation: A Universal Treatment Approach to DMD. End Duchenne Tour April 2018

DR.NEIL FRAZER CHIEF EXECUTIVE OFFICER & MANAGING 1

Transcription:

October 2017 The Outlook for Oncology: The Shrinking, Affordable Proton Therapy Center Focusing our energy on saving lives Jonathan Farr, DSc Senior Vice President Medical Physics

Forward Looking Statement This presentation may contain certain projections and other forward-looking statements with respect to the financial condition, results of operations, businesses and prospects of Advanced Oncotherapy plc ( AVO, Advanced Oncotherapy or the Company ). These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. Any of the assumptions underlying these forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in the forward-looking statements may not actually be achieved. Nothing contained in this presentation should be construed as a profit forecast or profit estimate. Investors or other recipients are cautioned not to place undue reliance on any forward-looking statements contained herein. Advanced Oncotherapy undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances. Neither this presentation nor any verbal communication shall constitute an invitation or inducement to any person to subscribe for or otherwise acquire securities in Advanced Oncotherapy.

How do we improve the targeted dose delivery with protons? Proton beam properties compared to photon Protons are charged particles That is why they release their energy in a precisely defined penetration depth in tissue In contrast, photons emit their energy along their entire path through tissue 1

Comparative Doses: Proton vs. Photon Therapy Approximately 40% of body doses are spared This is why it is especially suitable for children Organ damage can be reduced Higher doses are made possible Retreatments: Patients treated previously treated with radiation therapy 2

Proton therapy compared with photon therapy: Craniospinal (paediatric) 3

Expansion of Proton Therapy Worldwide 8+ 7+ 4 16 >200 MeV Operating Under construction 4

Equipment Size Comparison Proton vs. Photon Accelerator Gantry 5

Proton Therapy Accessibility Goals Smaller, lighter: accelerators, beamlines, and gantries. Efficiency equal or better than photon LINAC systems. Reduced maintenance costs. Flexible system fitting a range of geometries. Reduced install costs (shielding). Reduced decommissioning cost (up to 3x cost of the installation). Reduced operational costs (manpower, energy use). Ease of use, lower barriers to entry. 6

Harley Street Project 141/143 Harley Street Grade 2 listed buildings Challenge: Install and Operate a high energy Proton Therapy Center here Simon Baynham, Property Director at the Howard de Walden Estate, explains the Estate s decision to approach AVO saying; Such a facility should further enhance the tremendous work already being carried out in Harley Street, by some of the world s top oncologists and radiologists in the field of cancer. 7

Solution: the LIGHT System Proton Source RFQ Modulator SCDTL CCL Vacuum / Support system Treatment room Smaller emittance, pulsed energy changes efficiency, lightweight transport, less shielding Modular, no moving parts Reduced operational and maintenance costs. High flux hypofractionation 8

Solution: Gantry Alternative 9

AVO Harley Street Proton Therapy Centre Design 10

AVO Harley Street Progress Update Deconstruct began on site January 2017. Demolition and enabling work completed. Stage II sub-structural works (groundworks, piling and excavation) well underway. Building readiness on schedule for installation by H1 2019. LIGHT system installation and commissioning 2019. 2020 First patient. 11

Pebble Mill Project AVO is actively working with the Calthorpe Estate to deliver a compact LIGHT system in Birmingham 12

Thank you for your attention